Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T23:41:35.646Z Has data issue: false hasContentIssue false

Chapter 18 - Hematopoietic cell transplantation in older adults

from Part 3 - Management of hematologic malignancies in older adults

Published online by Cambridge University Press:  05 August 2011

By
Andrew S. Artz  and
William B. Ershler
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 260 - 273
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Xie, Y, Davies, SM, Xiang, Y. Trends in leukemia incidence and survival in the United States (1973–1998). Cancer. 2003;97:2229–2235.CrossRefGoogle Scholar
Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130.CrossRefGoogle ScholarPubMed
Appelbaum, FR, Gundacker, H, Head, DR. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.CrossRefGoogle ScholarPubMed
Leith, CP, Kopecky, KJ, Godwin, J. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329.Google ScholarPubMed
Fermand, JP, Levy, Y, Gerota, J. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 1989;73:20–23.Google ScholarPubMed
Barlogie, B, Alexanian, R, Dicke, KA. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70:869–872.Google ScholarPubMed
Clift, RA, Buckner, CD, Appelbaum, FR. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867–1871.Google ScholarPubMed
Lazarus, HM, Carreras, J, Boudreau, C. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008;14:1323–1333.CrossRefGoogle Scholar
Gratwohl, A, Baldomero, H, Frauendorfer, K. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37:1069–1085.CrossRefGoogle ScholarPubMed
Giralt, S, Estey, E, Albitar, M. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536.Google ScholarPubMed
Slavin, S, Nagler, A, Naparstek, E. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763.Google ScholarPubMed
Martino, R, Iacobelli, S, Brand, R. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846.CrossRefGoogle ScholarPubMed
Alyea, EP, Kim, HT, Ho, V. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–1814.CrossRefGoogle ScholarPubMed
Lima, M, Couriel, D, Thall, PF. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864.CrossRefGoogle ScholarPubMed
Slattery, JT, Clift, RA, Buckner, CD. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060.Google ScholarPubMed
Herbrecht, R, Denning, DW, Patterson, TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415.CrossRefGoogle ScholarPubMed
Nichols, WG, Corey, L, Gooley, T. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97:867–874.CrossRefGoogle ScholarPubMed
Kline, J, Pollyea, DA, Stock, W. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37:307–310.CrossRefGoogle ScholarPubMed
Manton, KG, Corder, L, Stallard, E. Chronic disability trends in elderly United States populations: 1982–1994. Proc Natl Acad Sci USA. 1997;94:2593–2598.CrossRefGoogle ScholarPubMed
Vasu, S, Leitman, SF, Tisdale, JF. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008;112:2092–2100.CrossRefGoogle Scholar
Richa, E, Papari, M, Allen, J. Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biology of blood and marrow transplantation. Biol Blood Marrow Transplant. 2009;11:1394–1399. Epub 2009 Sep 8.CrossRefGoogle Scholar
Kiehl, MG, Kraut, L, Schwerdtfeger, R. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816–2825.CrossRefGoogle ScholarPubMed
Weisdorf, DJ, Anasetti, C, Antin, JH. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971–1977.CrossRefGoogle ScholarPubMed
Kollman, C, Howe, CW, Anasetti, C. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051.CrossRefGoogle ScholarPubMed
Lee, SJ, Klein, J, Haagenson, M. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–4583.CrossRefGoogle ScholarPubMed
Mehta, J, Gordon, LI, Tallman, MS. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?Bone Marrow Transplant. 2006;38:95–100.CrossRefGoogle ScholarPubMed
Schetelig, J, Bornhauser, M, Schmid, C. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26:5183–5191.CrossRefGoogle ScholarPubMed
Narimatsu, H, Miyakoshi, S, Yamaguchi, T. Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. Blood. 2008;112:2579–2582.CrossRefGoogle ScholarPubMed
Uchida, N, Wake, A, Takagi, S. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant. 2008;14:583–590.CrossRefGoogle ScholarPubMed
Majhail, NS, Brunstein, CG, Tomblyn, M. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14:282–289.CrossRefGoogle ScholarPubMed
Konuma, T, Takahashi, S, Ooi, J. Myeloablative unrelated cord blood transplantation for acute leukemia patients between 50 and 55 years of age: single institutional retrospective comparison with patients younger than 50 years of age. Ann Hematol. 2009;88:581–588.CrossRefGoogle ScholarPubMed
Kusnierz-Glaz, CR, Schlegel, PG, Wong, RM. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. J Clin Oncol. 1997;15:18–25.CrossRefGoogle ScholarPubMed
Miller, CB, Piantadosi, S, Vogelsang, GB. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996;14:1327–1332.CrossRefGoogle ScholarPubMed
Gopal, AK, Gooley, TA, Golden, JB. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant. 2001;27:593–599.CrossRefGoogle ScholarPubMed
Qazilbash, MH, Saliba, RM, Hosing, C. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007;39:279–283.CrossRefGoogle ScholarPubMed
Jantunen, E, Canals, C, Rambaldi, A. Autologous stem cell transplantation in elderly patients (>= 60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008;93:1837–1842.CrossRefGoogle ScholarPubMed
Levi, I, Grotto, I, Yerushalmi, R. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leuk Res. 2004;28:605–612.CrossRefGoogle ScholarPubMed
Nathan, PC, Sung, L, Crump, M. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst. 2004;96:38–45.CrossRefGoogle ScholarPubMed
Ringden, O, Horowitz, MM, Gale, RP. Outcome after allogeneic bone marrow transplant for leukemia in older adults. J Am Med Assoc. 1993;270:57–60.CrossRefGoogle ScholarPubMed
Yanada, M, Emi, N, Naoe, T. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transplant. 2004;34:29–35.CrossRefGoogle ScholarPubMed
Aoudjhane, M, Labopin, M, Gorin, NC. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–2312.CrossRefGoogle Scholar
Carlens, S, Ringden, O, Remberger, M. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant. 1998;22:755–761.CrossRefGoogle ScholarPubMed
Ditschkowski, M, Elmaagacli, AH, Trenschel, R. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant. 2006;20:127–131.CrossRefGoogle ScholarPubMed
Wong, R, Giralt, SA, Martin, T. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052–3059.CrossRefGoogle ScholarPubMed
Stone, RM, Berg, DT, George, SL. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98:548–553.CrossRefGoogle ScholarPubMed
Artz, AS, Besien, K, Zimmerman, T. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: the University of Chicago experience. Bone Marrow Transplant. 2005;35:253–260.CrossRefGoogle ScholarPubMed
Estey, E, Lima, M, Tibes, R. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400.CrossRefGoogle Scholar
Cahn, JY, Labopin, M, Schattenberg, A. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia. 1997;11:416–419.CrossRefGoogle Scholar
Klingemann, HG, Storb, R, Fefer, A. Bone marrow transplantation in patients aged 45 years and older. Blood. 1986;67:770–776.Google ScholarPubMed
Przepiorka, D, Smith, TL, Folloder, J. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470.Google ScholarPubMed
Artz, AS, Pollyea, DA, Kocherginsky, M. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:954–964.CrossRefGoogle ScholarPubMed
Yancik, R, Ganz, PA, Varricchio, CG. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147–1151.CrossRefGoogle ScholarPubMed
Yancik, R, Havlik, RJ, Wesley, MN. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6:399–412.CrossRefGoogle ScholarPubMed
Alamo, J, Shahjahan, M, Lazarus, HM. Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Bone Marrow Transplant. 2005;36:475–479.CrossRefGoogle ScholarPubMed
Charlson, M, Szatrowski, TP, Peterson, J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251.CrossRefGoogle ScholarPubMed
Charlson, ME, Pompei, P, Ales, KL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.CrossRefGoogle ScholarPubMed
Diaconescu, R, Flowers, CR, Storer, B. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558.CrossRefGoogle ScholarPubMed
Sorror, ML, Maris, MB, Storer, B. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968.CrossRefGoogle ScholarPubMed
Sorror, ML, Maris, MB, Storb, R. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.CrossRefGoogle ScholarPubMed
Labonte, L, Iqbal, T, Zaidi, MA. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14:1039–1044.CrossRefGoogle ScholarPubMed
Kaplan, MH, Feinstein, AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387–404.CrossRefGoogle ScholarPubMed
Sorror, ML, Giralt, S, Sandmaier, BM. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–4613.CrossRefGoogle ScholarPubMed
Guilfoyle, R, Demers, A, Bredeson, C. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant. 2009;43:133–139.CrossRefGoogle Scholar
Majhail, NS, Brunstein, CG, McAvoy, S. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant. 2008;14:985–992.CrossRefGoogle Scholar
Artz, AS, Wickrema, A, Dinner, S. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:1209–1216.CrossRefGoogle ScholarPubMed
Lim, ZY, Ho, AY, Ingram, W. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol. 2006;135:201–209.CrossRefGoogle ScholarPubMed
Sorror, ML, Maris, MB, Sandmaier, BM. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819–3829.CrossRefGoogle ScholarPubMed
Sorror, M, Storer, B, Sandmaier, BM. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001.CrossRefGoogle ScholarPubMed
Inouye, SK, Peduzzi, PN, Robison, JT. Importance of functional measures in predicting mortality among older hospitalized patients. J Am Med Assoc. 1998;279:1187–1193.CrossRefGoogle ScholarPubMed
Giralt, S, Thall, PF, Khouri, I. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637.CrossRefGoogle ScholarPubMed
Sayer, HG, Kroger, M, Beyer, J. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant. 2003;31:1089–1095.CrossRefGoogle ScholarPubMed
Besien, K, Artz, A, Smith, S. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5728–5738.CrossRefGoogle ScholarPubMed
Gómez-Núñez, M, Martino, R, Caballero, MD. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplant. 2004;33:477–482.CrossRefGoogle ScholarPubMed
Repetto, L, Fratino, L, Audisio, RA. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.CrossRefGoogle Scholar
Lee, SJ, Lindquist, K, Segal, MR. Development and validation of a prognostic index for 4-year mortality in older adults. J Am Med Assoc. 2006;295:801–808.CrossRefGoogle ScholarPubMed
Extermann, M, Overcash, J, Lyman, GH. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–1587.CrossRefGoogle ScholarPubMed
Firat, S, Bousamra, M, Gore, E. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:1047–1057.CrossRefGoogle ScholarPubMed
Harris, TB, Ferrucci, L, Tracy, RP. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506–512.CrossRefGoogle ScholarPubMed
Masotti, L, Ceccarelli, E, Forconi, S. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med. 2005;258:145–152.CrossRefGoogle ScholarPubMed
Penninx, BW, Kritchevsky, SB, Newman, AB. Inflammatory markers and incident mobility limitation in the elderly. J Am Geriatr Soc. 2004;52:1105–1113.CrossRefGoogle ScholarPubMed
Min, CK, Kim, SY, Eom, KS. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse. Bone Marrow Transplant. 2006;37:493–498.CrossRefGoogle ScholarPubMed
Schots, R, Kaufman, L, Riet, I. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia. 2003;17:1150–1156.CrossRefGoogle ScholarPubMed
Fann, JR, Alfano, CM, Burington, BE. Clinical presentation of delirium in patients undergoing hematopoietic stem cell transplantation. Cancer. 2005;103:810–820.CrossRefGoogle ScholarPubMed
Falda, M, Busca, A, Baldi, I. Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol. 2007;82:863–866.CrossRefGoogle ScholarPubMed
Kroger, N, Shimoni, A, Zabelina, T. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006;37:339–344.CrossRefGoogle Scholar
Tsirigotis, P, Bitan, RO, Resnick, IB. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica. 2006;91:852–855.Google ScholarPubMed
Wallen, H, Gooley, TA, Deeg, HJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005;23:3439–3446.CrossRefGoogle ScholarPubMed
Gupta, V, Daly, A, Lipton, JH. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant. 2005;11:764–772.CrossRefGoogle ScholarPubMed
Corradini, P, Zallio, F, Mariotti, J. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol. 2005;23:6690–6698.CrossRefGoogle ScholarPubMed
Shimoni, A, Kroger, N, Zabelina, T. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005;19:7–12.CrossRefGoogle ScholarPubMed
Weisser, M, Schleuning, M, Ledderose, G. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant. 2004;34:1083–1088.CrossRefGoogle Scholar
Shapira, MY, Resnick, IB, Bitan, M. Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients. Bone Marrow Transplant. 2004;34:155–159.CrossRefGoogle ScholarPubMed
Bertz, H, Potthoff, K, Finke, J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol. 2003;21:1480–1484.CrossRefGoogle ScholarPubMed
Camara, R, Alonso, A, Steegmann, JL. Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older. Haematologica. 2002;87:965–972.Google ScholarPubMed
Deeg, HJ, Shulman, HM, Anderson, JE. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188–1194.Google ScholarPubMed
Du, W, Dansey, R, Abella, EM. Successful allogeneic bone marrow transplantation in selected patients over 50 years of age – a single institution's experience. Bone Marrow Transplant. 1998;21:1043–1047.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×